Technical Analysis for NVUS - Novus Therapeutics, Inc.

Grade Last Price % Change Price Change
grade D 4.25 8.42% 0.33
NVUS closed up 8.42 percent on Tuesday, March 19, 2019, on 65 percent of normal volume.

Earnings due: Apr 1

*** please verify all earnings dates ***

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent Down Up Up
See historical NVUS trend table...

Date Alert Name Type % Chg
Mar 19 MACD Bullish Centerline Cross Bullish 0.00%
Mar 19 Lower Bollinger Band Walk Weakness 0.00%
Mar 19 Wide Bands Range Expansion 0.00%
Mar 19 Oversold Stochastic Weakness 0.00%
Mar 18 MACD Bearish Centerline Cross Bearish 8.42%
Mar 18 50 DMA Support Bullish 8.42%
Mar 18 Lower Bollinger Band Walk Weakness 8.42%
Mar 18 Wide Bands Range Expansion 8.42%
Mar 18 Lower Bollinger Band Touch Weakness 8.42%
Mar 18 Oversold Stochastic Weakness 8.42%

Older signals for NVUS ...

Free Daily (Stock) Chart Reading

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:
Profile
Novus Therapeutics, Inc., formerly Tokai Pharmaceuticals, Inc., is a pharmaceutical company. The Company is focused on the acquisition, development, and commercialization of ear, nose, and throat products. It has two platforms: OP-01 Foam Platform and OP-02 Surfactant Program. OP-01 is developed with the intent to be used as a delivery vehicle for drugs treating ears, as well as the nasal and sinus cavities. OP-01 is currently being developed as an improved treatment option for acute otitis externa. OP-02 is a daily nasal spray that is designed to improve and maintain a healthy middle ear. OP-02 is being developed as a potential treatment option for patients with otitis media and Eustachian tube dysfunction. OP-02 is a combination drug product, which comprises two components: surfactant dipalmitoylphosphatidylcholine and a spreading agent cholesteryl palmitate. The product is sprayed through the nostrils toward the opening of the Eustachian tube at the back of the nasal cavity.
Medicine Pharmaceutical Otorhinolaryngology Ear Pediatrics
Is NVUS a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 1 bullish, 2 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 8.61
52 Week Low 1.52
Average Volume 31,488
200-Day Moving Average 4.5404
50-Day Moving Average 3.7224
20-Day Moving Average 4.413
10-Day Moving Average 4.108
Average True Range 0.388
ADX 23.97
+DI 20.7173
-DI 20.0563
Chandelier Exit (Long, 3 ATRs ) 4.046
Chandelier Exit (Short, 3 ATRs ) 4.664
Upper Bollinger Band 5.1871
Lower Bollinger Band 3.6389
Percent B (%b) 0.39
BandWidth 35.08271
MACD Line 0.0026
MACD Signal Line 0.1152
MACD Histogram -0.1126
Fundamentals Value
Market Cap 29.51 Million
Num Shares 6.94 Million
EPS -3.46
Price-to-Earnings (P/E) Ratio -1.23
Price-to-Sales 0.00
Price-to-Book 1.14
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 4.78
Resistance 3 (R3) 4.72 4.48 4.69
Resistance 2 (R2) 4.48 4.35 4.51 4.66
Resistance 1 (R1) 4.37 4.27 4.43 4.43 4.63
Pivot Point 4.13 4.13 4.16 4.16 4.13
Support 1 (S1) 4.02 4.00 4.08 4.08 3.87
Support 2 (S2) 3.78 3.92 3.81 3.84
Support 3 (S3) 3.67 3.78 3.81
Support 4 (S4) 3.73